AU593608B2 - Hydrophobic CIS-platinum complexes efficiently incorporated into liposomes - Google Patents

Description

Fr COM MON1 WE AL T H OF A U S T R A L I A PATENT ACT 1952 COMPLETE SPECIFICATION (original'~ insth (Original) amen.dmcilts vcuidr FOR OFFICE USE L ,Aij 49 wid is correCct for pi01 (n Class Int. Class Application Number: Lodged: Complete Specification Lodged: Accepted: Priority: .wi1nr-'JA by lh2o SRelated Art: anti is coar. lmin t t* NAmdes ofo Applican BOARDE O& REGENTS, TH en NIVERSI ys FTXSSSE Thdes lofin Apliamnt i uldsrpino hsivnin inldn the 201t Westo 7th Strfreegt Aunw ou

-,I

i t UTSC:050 a S.

*9

S

*a S

S

S

HYDROPHOBIC CIS-PLATINUM COMPLEXES EFFICIENTLY INCORPORATED INTO LIPOSOMES 0t r L.

In v This invention relates to newly synthesized platinum complexes with hydrophobic properties. The use of liposomes incorporating these new and previously synthesized complexes in anti-tumor chemotherapy is also described.

Cis-platinum (CDDP) is a highly effective drug in the treatment of several neoplastic diseases in humans (Loehrer et al (1984) Ann. Int. Med. V 100, pp 704-713).

However, its use is limited by severe systemic toxicity, particularly nephrotoxicity and neurotoxicity (Zwelling et al Platinum Complexes. In: Pharmacologic principles of cancer treatment (1982) Ed by B.A. Chabner, Saunders, Philadelphia, PA). In an attempt to modify the therapeutic index of CDDP, new derivatives have been synthesized during the last decade. However, the development of some promising analogues has been prevented by their low hydrosolubility, which decreases their potential for clinical use (Burchenal et al (1979) Cancer Treat. Rep. V 63, pp 1493-1497).

cCI AC I I i: 'i

'I

i X, i I~ 3 -2- Liposomes are lipid vesicles which may form spontaneously upon addition of an aqueous solut o a dry lipid film (Mayhew et al, In: Liposomes (1983) Ed by Marc J. Ostro, Marcel Dekker, Inc., New York, Liposomes may be used as drug carriers of hydrophobic or hydrophilic drugs entrapped in their hydrophobic or hydrophilic compartments respectively. Multilamellar liposomes are multilayer lipid vesicles (MLV) that are particularly suited for carrying hydrophobic drugs since their hydrophobic compartment is larger than their hydrophilic compartment. When injected intravenously (iv) in animals, (Kasi et al (1984) Int. J. Nucl. Med. Biol. V 11 pp 35-37, Lopez-Berestein et al. (1)(1984) Cancer Drug Deliv. V 1, pp 199-205) and humans (Lopez-Berestein et al 15 (2)(1984), Cancer Res. V 44, pp 375-378), MLV concentrate in the liver, spleen and other organs rich in reticuloendothelial (RES) cells.

Liposomes have been previously used in vitro to deliver chemotherapeutic agents, (Mayhew et al, Liposomes (1983), Ed by Ostro, Marcel Dekker, Inc., New York, N.Y.) and immunomodulators and anti-fungal agents in vitro (Mehta et al (1984), Immunology V 51 pp 517-527, and in vivo in animals (Lopez-Berestein et al (4)(1984) Clin Exp Metastasis V 2 pp 127-137 and Lopez-Berestein et al (1983), J Inf Dis V 147, pp 937-945) and in humans (Lopez-Berestein et al (1985) J. Inf. Dis. V 151 pp 704- 710).

Recent studies show that liposomes can reduce certain types of drug-related toxicities such as doxorubicin cardiotoxicity (Forssen et al (1981) Proc. Natl. Acad.

Sci. V 78 pp 1873-1877, Olson et al (1982), Eur. J. Cancer Clin. Oncol. V 18 pp 167-176, Gabizon et al (1982) Cancer Res. V 42 pp 4734-4739, Herman et al (1983) Cancer Res. V 43 pp 5427-5432) and CDDP nephrotoxicity, (Freise et al 77 f^ S^ 1*

Q

;i i r~ -3- (1982), Arch. Int. Pharmacodynamie Therapie V 258 pp 180- 192) and may increase antitumor activity as a result of a slow release mechanism (Mayhew et al (1978) Ann. N.Y.

Acad. Sci. V 308, pp 371-386, Patel et al (1984) Int. J.

Cancer V 34 pp 717-723) a higher drug uptake by tumor cells or due to a more selective organ distribution (Gabizon et al (1983) Cancer Res. V 43, pp 4730-4735 and Mayhew et al (1983), Cancer Drug Deliv. V 1 pp 43-58). In U.S. Patent No. 4,330,534 N4-acylcytosine arabinoside incorporated into liposomes, for example, was found to be therapeutically effective when administered to tumorbearing animals. In spite of these promising results, the clinical application of antitumor agents encapsulated in liposomes has been delayed, mainly due to formulation, 15 drug stability and large scale production problems.

.CDDP has been previously encapsulated in MLV but with a very low encapsulation efficiency and poor stability (75% at 48 hours in 0.9% NaCl solution) (Freise et al (1982) Arch. Int. Pharmacodynamie Therapie V 258 pp 180-192).

1 t t In U.S. Patent No. 4,256,652 are described certain io c platinum compounds comprising resolved stereoisomers of 1,2 diaminocyclohexane (DACH). The isomers utilized were cis-DACH, trans-RR-DACH and trans-SS-DACH. The platinum compounds described therein contained, in addition to a resolved DACH isomer, two hydrophilic platinum ligands such as bromide, iodide, nitrate, bromoacetate, sulfate or glucuronate. The platinum compounds comprising the trans-RR-DACH were described as often more therapeutically i effective than those bearing cis-DACH.

In European Patent Application No. 83306726.7 certain platinum compounds are described which may comprise diaminocyclohexane (non-stereochemically resolved) and do 77, w 7 i 1 1

I--

I i~4- IC-i (13 l l -4comprise phosphatidyl groups having fatty acid substituents. These compounds are described as largely insoluble in plasma and preferably employed with lipid vesicle carriers. The platinum compound-phospholipid vesicles were preferably prepared by a sonic oscillation procedure which characteristically yields unilamellar vesicles.

The present invention comprises a platinum (II) four-coordinate complex having the formula: S *9 9 9 9o Pt (II) 9 ar 9r 9tr 9 o 49 99 4 In this formula R 1 and R 2 are each carboxylates bearing a hydrophobic radical function, most preferably neodecyl, or, when linked together, are a dicarboxylato bearing a hydrophobic radical function. The R 3 and R 4 are each:

H

i~ 9 4 4 N R In this latter formula, R 5 is selected from the group consisting of hydrogen, an alkyl having from to carbon atoms such as isopropyl, aryl, aralkyl, alkenyl, a cycloalkyl such as cyclohexyl, cycloalkenyl and a r 1 r i ';i combination thereof. R 5 is preferably hydrogen, alkyl having between 1 and 20 carbon atoms, more preferably between 6 and 12 carbon atoms and most preferably between 2 and 6 carbon atoms or cycloalkyl having between 3 and 12 carbon atoms.

Additionally R 3 and R 4 may be linked together in a single function. When R 3 and R 4 are so linked together, preferred cycloalkyl-1,2-diamino component is 1,2diaminocyclohexare, preferably in the trans-R,R- or trans-S,S- form.

In the above-described complex the carboxylato of R 1 and R 2 is preferably an alkylcarboxylato having between about 5 and 20 carbon atoms, an arylcarboxylato wherein aryl is phenyl, naphthyl, or an alkylphenyl wherein the alkyl phenyl has between about 12 and 16 carbon atoms.

When the complex contains R 1 and R 2 as a dicarboxylato, the dicarboxylato is preferably an alkyldicarboxylato having between about 5 and 20 carbon atoms, or an aryldicarboxylato wherein aryl is naphthyl, phenyl, or alkylphenyl wherein the alkyl of the alkylphenyl has between about 6 and 12 carbon atomseAs used in the above description the term aryl is defined further as a function preferably having between about 6 and 14 carbon atoms. Likewise the term alkenyl is preferably a function having between about 5 and 20 carbon atoms.

The cycloalkyl referred to in the present descriptions is preferably a function having between about 3 and .4 t T I -6- 12 carbon atoms. The cycloalkenyl term as used above is preferably a function having between about 5 and 20 carbon atoms. The term artlkyl as used above is a function preferably having between about 7 and 20 carbon atoms and contains linked aryl and alkyl portions. The aryl portion herein preferably has between about 6 and 10 carbon atoms and the alkyl portion preferably has between about 1 and carbon atoms. When R 3 and R 4 are taken together they are preferably a cycloalkyl-1,2-diamino having between about 3 and 20 carbon atoms. The alkyl ring of the cycloalkyl preferably has between about 3 and 12 carbon atoms.

44t 4 44 A further aspect of the present invention concerning So". 15 the platinum (II) four-coordinate complex having the I formula: R

R

1 S r Pt (II)

R

4

R

2 *t t concerns the case where R 1 and R 2 taken together, are a dicarboxylato, preferably a cis dicarboxylato, of the formula: I 7 1 ii:; -7- OOC CH N R 6 OOC CH 4 4 0 4 0 0 where R 6 is alkyl having between about 10 and 20 carbon atoms, preferably pentyl, neopentyl, decyl or neodecyl and R7and R 8 are each hydrogen or an alkyl having between about 1 and 5 carbon atoms.

As described above R 3 and R 4 are each: 2f H -N R

H

C C k t'.

When R 3 and R 4 are taken together they are selected from the group consisting of cycloalkyl-1,2-diamino having between about 3 and 7 carbon atoms, and alkyl-1,2-diamino having between about 2 and 12 carbon atoms. The cycloalkyl-1,2-diamino is preferably 1,2diaminocyclohexane and more preferably trans-R,R-l,2diaminocyclohexane or trans-S,S-1,2-diaminocyclohexane.

This complex is, as described above, substantially soluble in methanol or chloroform and substantially insoluble in water.

77 -o -;j-I r;phospholipids, optionally cholesterol, and the fourcoordinate platinum complexes described above, as well as the preparation and uses of these liposomes. Liposomes of the present invention contain the platinum complex and the phospholipid in a preferred ratio between about 1 to and about 1 to 30, a more preferred ratio being 1 to Preferred phospholipids of these liposomes include phosphatidylglycerol, phosphatidylcholine, sphingomyelin, phosphatidic acid or phosphatidylserine, the more preferred phospholipids being phosphatidylglycerol, phosphatidylcholine or a combination thereof. The most 15 preferred phosphatidylglycerol is one consisting Sessentially of dimyristoylphosphatidylglycerol and the most preferred phosphatidylcholine is one consisting essentially of dimyristoylphosphatidylcholine. When the liposomes of the present invention comprise 20 dimyristoylphosphatidylglycerol and dimyristoylphosphatidylcholine they are preferably in a ratio between about 1-10 and 10-1, more preferably in a ratio of about 3 to 7.

The liposomes of the present invention may be multilamellar, unilamellar or have an undefined lamellar t construction. A pharmaceutical composition comprising the liposomes of and a pharmaceutically acceptable carrier or diluent may be used for the therapy of disease conditions such as cancer.

A focal point of the present invention involves a method of treating a host animal afflicted with tumor cells sensitive to the presence of a platinum (II) fourcoordinate complex. This method comprises administering to the host an amount of the platinum (II) four-coordinate I I -9complex described above or a liposome of the present invention comprising a phospholipid and a tumor cellinhibiting effective amount of said platinum complex. The administering step is preferably parenteral and by intravenous, intraarterial, intramuscular, intralymphatic, intraperitoneal, subcutaneous, intrapleural or intrathecal injection or by topical application or oral dosage. Such administration is preferably repeated on a timed schedule, for example twice daily for a period of two weeks. The treatment may be maintained until tumor regression or disappearance has been achieved and may be used in conjunction with other forms of tumor therapy such as surgery or chemotherapy with different agents.

15 These antitumor methods may also be used to inhibit the metastatic spread of tumors such as reticulosarcoma. A preventative pretreatment with the platinum(II) complexes or liposomes comprising those complexes may be used to Spreclude metastatic spread in a vaccination-like manner.

Platinum (II) four-coordinate complexes were prepared utilizing racemic (unresolved) DACH, trans-RR-DACH or trans-SS-DACH. It was found that platinum complexes comprising trans-RR-DACH or trans-SS-DACH and two hydrophobic ligands such as cyclopentene-carboxylato were Smore efficiently incorporated into liposomes than were the analogous complexes comprising racemic DACH.

Liposomes incorporating these platinum complexes were found to be stable in an aqueous milieu, non-nephrotoxic 7 and active against murine leukemia L-1210.

In a general sense, the square-planar platinum (II) four coordinate complexes of the present invention have the formula: 1

R

R Pt(II) 3

R

where R 1 and R 2 are preferably carboxylato monoanions bearing a hydrophobic radical function. R 1 and R 2 may also be a single carboxylato dianion where the carboxylato groups are bound to an interlinking atom which in turn is bound to a radical function. Additionally, R 3 is a vicinal diaminoalkane or vicinal diaminocycloalkane. It is contemplated that R 3 may be composed of two independent alkylamines, cycloalkylamines or ammonia. These 15 components confer upon the complex a substantial solubility (normally greater than about 5.0 mg/ml) in methanol or chloroform at ambient temperatures and a substantial insolubility (less than about 0.5 mg/ml) in S. aqueous solutions at ambient temperatures.

0 The hydrophobic radical function, that function covalently pendant from the carboxyl group or from an intermediate or linking group, may be an alkyl, c substituted aryl, aryl, alkenyl, cycloalkyl or

S

c 25 cycloalkenyl group or even combinations of these functions such as alkylaryl or arylalkenyl, to name but two of the many possible hydrophobic combinations. The hydrophobic radical function characteristically has between 5 and carbon atoms. When this hydrophobic radical function comprises an alkyl or alkenyl group, this group may be S' straight or branched. Polar functions such as hydroxyl groups, for example, substituted on the hydrophobic radicals would tend to lessen their hydrophobicity and may render them less useful for the purposes of the present invention.

A- ,-tI 'iL 1 1 1 11 1 i -r -11- I In certain cases the R 1 and R2 functions may be interlinked, for example when two acetate or propionate functions are bound together by a nitrogen atom. In these cases the R 1 and R 2 functions are a single carboxylato dianion. An alkyl hydrophobic function having between six and twenty carbon atoms, such as n-decane, for example, may be bound to the interlinking nitrogen and the resultant compound utilized in the production of the platinum (II) four coordinate complex of the present invention.

With certain hydrophobic radical functions (cyclopentene, for example) present on the carboxylato monoanion it was found that efficient incorporation of PT 15 complexes into phospholipid liposomes was dependent on characteristics of the R 3 function. For example, when R 3 4 *was 1, 2 diaminocyclohexane (DACH) the amino groups -ay be ri in several relative stereochemical configurations, cis, trans-RR and trans-SS (a mixture of these being termed 20 "racemic"). With platinum (II) complexes containing cyclopentene radical functions (R 1 and R 2 and various stereochemical types of DACH it was found that the trans- RR-DACH and trans-SS-DACH-complexes were more efficiently incorporated into phospholipid liposomes (vesicles being a S 25 term equivalent to liposomes) than were the analogous ;racemic DACH complexes.

When a hydrophobic radical functlon was a branched S alkyl containing nine carbon atoms such as that in neodecanoato,

(C

0

H

20 0 2 empirical formula) the incorporation efficiency of a platinum (II) complex comprising racemic DACH or trans-RR-DACH was maximal Thus, linear or branched alkyl radical functions having from about 6 to about 12 carbon atoms confer properties of efficient phospholipid liposome incorporation upon any DACH-containing Pt (II) complex.

St 77 t i

I

J i

F

-12- Liposomes containing the platinum (II) complexes described herein may be prepared from various amphipathic substances including natural or synthetic phospholipids.

The phospholipids usable to produce liposomea are numerous and not exhaustively listed herein since they are generally well known in the art. These phospholipids include but are not limited to: lecithin, phosphatidylethanolamine, lysolecithin, lysophatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, .0 cardiolipin, phosphatidic acid and the cerebrosides. Most preferable phospholipids for the practice of aspects of the present invention include dimyristoylphosphatidylglycerol (DMPG) and dimyristoylphosphatidylcholine

(DMPC).

Cholesterol in minor proportions ranging from less than 1% 15 to about 50% may be included with phospholipids and platinum (II) complexes to produce liposomes of the present invention. A preferable but not limiting combination of DMPG and DMPC has been found to be a ratio of 3 to 7 although ratios between 1:10 and 10:1 are contemplated as satisfactory. Ratios of platinum (II) complex to phospholipid between about 1 to 10 and about 1 to 30 are contemplated as generally satisfactory although .a 1 to 15 ratio was primarily used in studies thus far.

Either unilamellar or multilamellar or other platinum (II) complex containing liposomes may be used in the practice of the present invention. Multilamellar liposomes are presently preferred since the platinum (II) Scomplexes of the present invention are substantially water insoluble and they appear to be incorporated into the phospholipid bilayers of the liposome lamellae.

Generally, the procedure for synthesis of the platinum II compounds of the present invention may be described on one scale as follows: about 10 mmole vicinal diamino cycloalkane or alkane are added to 50 ml 7 |7 I-J *e~1Cre aA aqueous solution of K 2 Pt C1 4 (3.5 g) and stirred for six to eight hours at room temperature. The yellow solid formed comprising cis-bis-dichloro-1,2-diamine-Pt(II) may be removed by filtration and washed with fluids such as water, methanol or acetone. The solid may then be suspended in about 20 ml H 2 0 and an aqueous solution containing about 0.75 g Ag 2

SO

4 added thereto. After stirring for about 24 hours in the dark, precipitated Ag Cl may be removed by filtration. The sulfato-vicinal diamine-Pt may then be dissolved in about 100 ml H 2 0 and added to about 2 m mol of alkali earth metal salt of a carboxylato anion prepared in situ, and stirred therewith for about 30 minutes. After removal of BaSO 4 by filtration, the platinum II complex of the present ea' 15 invention may be obtained, for example by crystallization or removal of the solvent by evaporation.

f f The methods of preparation of particular platinum S, (II) complexes and chemotherapeutic treatment with particular platinum (II) complexes described in the Examples contained later herein are readily adapted to the production and use of analogously described and claimed complexes by simple substitutions of appropriate vicinal diamines or hydrophobic radical-containing carboxylato monoanions.

Liposomes comprising phospholipids and platinum complexes (Pt-liposomes) of the present invention are Suseful in inhibiting both the growth and metastatic spread of tumors.

Such Pt-liposomes may be administered parenterally, topically or cl'ally. Oral or parenteral dosages of these Pt-liposomes between about 2.5 mg/kg body weight and mg/kg body weight are contemplated as adequate in most conditions. The particular dosages, if a tumor-bearing S 1Se P 4j4N X j -14f human is being treated may vary in each case according to the condition of the patient, the type and extent of tumor, and particular Pt-liposome toxicity.

The amount of liposomal-platinum included in the pharmaceutical composition and the dosage utilized in the method of treatment of the invention will vary depending in each case upon the conditions of the patients, the nature of the tumor undergoing treatment, antitumor activity of liposomal-platinum, the toxicity and solubility characteristics thereof, etc. Liposomalplatinum may also be administered in combination with other antitumor agents in a combined therapeutic regimen.

15 Parenteral administration may be intraperitoneal, subcutaneous, intrapleural, intrathecal, intraurethral, intravenous, intraarterial, intramuscular or intralym- I phatic. Such parenteral administration preferably S. involves Pt-liposome suspensions in pharmaceutically acceptable solutions such as sterile isotonic aqueous solutions. These suspensions may be obtained fully prepared or may be prepared from preformed components. As known to those skilled in the art, Pt-liposomes may be prepared as pellets or powders. These pellets or powders may be mixed with pharmaceutically acceptable solutions to J I form suspensions for parenteral administration.

STopical administration of Pt-liposomes may involve S' pharmaceutical compositions such as suspensions, creams or -S i 30 ointments which may be obtained fully prepared or prepared from Pt-liposome powders or pellets. Such topical administration may be near to sites of cancerous lesions such as the epithelium or mucosa for example.

Oral administrations of Pt-liposomes preferably involve encapsulation of Pt-liposome powder or pellets 77 4 4'p 4* 4.

*0 Ir C

C(

whereby the Pt-liposomes are protected from much gastric and intestinal digestive activity before release from the encapsulation.

When desired, Pt-liposomes may be prepared to contain, for example, other therapeutic agents for treatment of tumors or anti-oxidants to aid in liposome stabilization.

Use of the complexes of the present invention, particularly as a component of liposomes, focuses upon the inhibition of tumor growth and prevention of the metastatic spread of tumors. For example, first a host is identified as bearing a tumor type known to generally contain cells whose growth is often inhibited by platinum (II) complexes. Tumor growth in the host may be inhibited by administering to the host the PT-containing liposomes of the present invention.

Similarly, the metastatic spread of tumors in a host may be inhibited. A host bearing metastatic or potentially metastatic tumors of a type noted often to be sensitive to platinum (II) complexes, would first be identified. The administration of the PT-containing liposomes of the present invention to that host would serve to inhibit metastatic spread.

The following examples are presented to further illustrate preferred embodiments of the present invention; they are not intended to limit the invention unless otherwise so stated in the accompanying claims.

II

-16- EXAMPLE 1 Materials and Analyses

K

2 PtC1 4 was purchased from AESAR (Johnson Matthey, Inc. Seabrook, NH). Cyclopentenecarboxylic acid was purchased from Pfaltz and Bauer, Inc., Stamford, CT; 1,2diaminocyclohexane (DACH) from Aldrich Chemical Co., Milwaukee, WI., trans-RR-DACH and trans-SS-DACH from Mortol Thiokol, Inc., Danvers, MO., and neodecanoic acid from Exxon Chemical Co., Houston, Texas. Elemental analyses on the platinum complexes were performed by Integral Microanalytical Laboratories, Inc., Raleigh, NC and by Robertson Laboratory, Inc., Florham Park, N.J.

Infrared spectra of the complexes (as KBr pellets) were measured in the range of 600-4000 cm 1 using a Nicolet 6000 Fourier transform infrared spectrophotometer.

C Chromatographically pure (thin-layer chromatography) dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG) used in this study were obtained from Avanti Polar Lipids (Birmingham, AL).

Cholesterol was purchased from Sigma Chemical Co. (St.

Louis, MO).

SEXAMPLE 2 i Synthesis of cis-bis-cyclopentenecarboxylato- S1,2-DACH-platinum (II) Cis-bis-cyclopentenecarboxylato-l,2-DACH-platinum (II) was one cis-platinum (CDDP) hydrophobic analogue used as a prototype to develop liposomal-platinum (L-PT) preparations. The general structure of this particular complex was as follows: S4i TO r -17- This prototype was synthesized using a multi-step procedure as described for racemic DACH (Khokhar et al.

Inorg. Chem. Acta. Bioinorganic Section, V 108, p 63 (1985) follows: 0.96 g of DACH were added to a filtered aqueous solution of K 2 PtC14 (3.5 g in 50 ml H 2 0) and the mixture was stirred for six to eight hours at room t 15 temperature. The yellow solid containing cis-bisdichloro-DACH-Pt (II) was removed by filtration and washed with H 2 0, methanol, and finally acetone. After the final product was dried under vacuum, the yield was calculated to be 56%. Subsequently, 1.0 g of cis-bis-dichloro-DACH- Pt (II) was suspended in 20 ml H 2 0 and an aqueous solution of Ag 2

SO

4 (0.75 g in 150 ml H 2 0) was added to obtain water soluble sulfato-DACH-Pt HO 2 The reaction mixture was S.stirred in the dark for 24 hours and the precipitated AgCl was removed by filtration. The yellow solution was evaporated to dryness at 45-50'C under reduced pressure and the yellow roduct was further dried over P 2 0 5 in vacuum. The yield of sulfato-DACH-Pt (II) H 2 0 was Finally, 0.423 g (1 mmol) of sulfato-DACH-Pt (II) was dissolved in 100 ml of H 2 0, and the barium cyclopentene- 30 carboxylato was prepared in situ by the addition of 0.3 g of Ba(OH) 2 to 0.226 g (2 mmol) of cyclopentenecarboxylic acid in H 2 0. These components were mixed and the reaction 2 mixture was stirred for 30 minutes at room temperature.

The BaSO 4 precipitate was filtered off, and the yellow filtrate was evaporated to dryness at 45'C under reduced pressure using a rotary evaporator. A yellow solid was Sec 77 Tj 1 1 1 T 1

-L

-18obtained, which was purified from methanol. The product was finally dried under vacuum. Yield was 70%. Analysis: C 40.26%, H 5.65% and N 5.05% C 18 H30N 2 0 4 Pt (PT) (theoretically C 40.67%, H 5.65% and N 5.27%. The infrared spectrum for the complex (as KBr pellet) /C=0 -1 -1 1632 cm and /C-0 1398 cm.

Cis-bis-cyclopentenecarboxylato-l,2-DACH-Pt (II) is highly soluble in methanol and chloroform and only slightly soluble in water (less than 0.5 mg/ml). The above-described synthetic procedure was carried out with both trans-RR-DACH and trans SS-DACH to produce the trans-RR and trans-SS isomers of cis-bis-cyclopentenecarboxylato-l,2-DACH-Pt The analysis of cis-bis- 15 cyclopentenecarboxylato-l,2-trans-RR-DACH-Pt (II)-3H 2 0 2 -o"0 was: C-37.36%, H-5.50%, N-5.12% (theoretically C-37.93%, H-5.82%, N-4.80%).

4 t V EXAMPLE 3 Synthesis of Cis-Bis-Neodecanoato- DACH-Platinum

(II)

Sulfato-racemic-DACH-platinum (II) (0.423 g), prepared as described in Example 2, was dissolved in 10 ml water. A potassium salt of neodecanoic acid (0,420 g) was added to this solution and the reaction mixture stirred for 30 minutes at room temperature. A gummy mass was obtained which was extracted in chloroform and the chloroform extract was dried over anhydrous MgSO 4 The 7 sMgSO 4 was separated by filtration and the filtrate evaporated to dryness. An off-white solid product was obtained which was dried in vacuo and over P 2 0 5 This final product was stored at OOC.

S. 77 l

:V

r

I

in CIIt.

-19- The elemental analysis of the final product was: C- 48.30%; H-8.10% and N-3.92%. The calculated elemental values for a compound of the empirical formula;

C

26

H

52

N

2 04Pt. is: C-47.93%; H-8.00% and N-4.30%.

The structural formnla of the cis-bis-neodecanoato- DACH-platinum II was as iollows: -NH2 Pt -boc--

R

C

R"

NH

2 t t t t tC r t c C C t t c C *CC t CC fr e? where can be: CH 3

C

2

H

5 or C 3

H

7 to give a carboxylato radical function C 10

H

19 0 2 (MW 172) as empirical formula.

Cis,bis-neodecanoato-DACH-platinum (II) was highly soluble in methanol and chloroform and insoluble in water.

The above described procedure was carried out with trans-RR-DACH to produce the trans-RR isomer of cis-bisneodecanoato-DACH-Platinum The analysis of cisbis-neodecanoato-RR-DACH-Platinum (II) was: C-47.75%, H- 8.16%, N-3.98% (theoretically C-47.93%, H-8.00%, N-4.30%).

30 EXAMPLE 4 Synthesis of Cis-Bis-n-Decyliminodiacetato- DACH-Platinum (II) Sulfato-DACH-platinum (II) H 2 0 (0.423 prepared as described in Example 2, was dissolved in 10 ml of H 2 0.

Ii

-C

I. V C I I

C

i:' -i I

I

'i Vj I The sodium salt of n-decyliminodiacetic acid was prepared in situ by the addition of NaOH (0.08 g) to N-decyliminodiacetic acid (0.273 g) in 50 ml of water. This aqueous solution of sodium N-decyliminodiacetato was added to the sulfato-DACH-platinum solution and stirred for 30 minutes at room temperature. The resulting solution was evaporated to dryness on a rotary evaporator at 40 0 C under reduced pressure. The yellow solid thus obtained was dissolved in methyl alcohol and filtered through Celite.

The yellow filtrate was evaporated to dryness in a rotary evaporator under reduced pressure. A yellow crystalline product was obtained, which was further purified from 1propanol, yield 15 An elemental analysis of the product showed: C-39.28; 4 i4 H-7.12% and N-6.68%. The theoretical composition for a t compound of the empirical formula, C 20

H

39

N

3 4 Pt.

2

H

2 0, was: C-38.95%; H-7.02% and N-6.81%. The infrared spectrum for -1 the complex (as KBr pellet) C=0 1580cm and C-0 1410cm 1 The structural formula of the cis-bis-n-decylimino- 4* diaceto-DACH-platinum (II) is shown as follows: 44 44

NH

2 OOC CH Pt N- R

NH

2 OOC CH 2 2 2 2 r ii n 5 F, i i 1 ~-~acci i-; -21- C CC C C C C

C

tc

C"

C 'C where R n-decyl or a longer straight or branched chain alkyl radical.

Cis-bis-n-decyliminodiacetato-DACH-Platinum (II) is highly soluble in methanol and chloroform and insoluble in water. The above described synthetic procedure was carried out with trans-RR-DACH to produce the trans-RR isomer of cis-bis-n-decyliminodiacetato-DACH-Pt The analysis of cis-bis-n-decyliminodiacetato-trans-RR-DACH-Pt (II) was: C-38.60%, H-6.87%, N-6.82% (theoretically C- 38.95%, H-7.02%; N-6.81%).

The above described compound represents a structure where R 1 and R 2 of the earlier described general structure 15 are one and the same and the carboxylato monoanions are bound together by a linking atom bearing an alkyl hydrophobic radical to form, in fact, a carboxylato dianion.

EXAMPLE Platinum-Containing Liposomes (L-PT) Multilamellar lipid vesicles (MLV) or liposomes containing incorporated platinum complexes (PT) of the above descriptions were prepared as previously described for other compounds (Lopez-Berestein et al (4)(1984) Clin.

Exp. Metastasis V 2 pp 127-137 and Lopez-Berestein et al (1983) J Inf Dis V 147 pp 937-945). In brief, chloroform 30 solutions of lipids (at the desired molar ratio) and PT were mixed at a lipid-PT ratio of 15:1 and the chloroform was evaporated in a rotary evaporator (Buchi, Brinkmann Instruments, Westbury, NY). The dried lipid film cbtained, containing PT, was then dispersed with an aqueous solution NaC1 in water) by vigorous handshaking. The suspension was subsequently centrifuged crCC -22at 30,000 x g for 45 minutes, the supernatant was discarded, and the pellet containing PT was resuspended in 0.9% NaCI solution.

MLV or liposomes containing platinum complexes may also be prepared from a lyophilized powder containing lipid and platinum compound. The lipid and platinum compound are dissolved in the hydrophobic solvent tertiary butanol 26 0 C) at the ratios described above. The solution is freeze-dried and a white powder obtained. MLV containing the platinum compound are formed upon the addition of 0.9% NaCL solution in water to the yophilized powder with mild shaking by hand.

EXAMPLE 6 FY Calculation of Encapsulation t Efficiency (EE) and Stability i t r f 20 Elemental platinum (Pt) was determined in the liposome suspension and the pellet by x-ray fluorescence as previously reported (Seifert et al (1979) Proc. Amer.

Ass'n. Cancer Res. V 20 p. 168) in the Department of Analytical Chemistry, The University of Texas Medical School at Houston, TX. The amount of platinum complex (PT) was determined in the supernatant by ultraviolet (UV) S'spectrophotometry using a wavelength of 224 nm. The EE was initially calculated with the two following formulas: 1. EE Pt in pellet/total Pt in the initial fc jliposome suspension 2. EE Total Pt initially added Pt in supernatant/total Pt initially added Since the results obtained by these two methods were highly comparable and the second method only requires PT 7 7 n i M 1 1 11 1 1 1 1 1 1 1 i -23determination by UV spectrophotometry, most EE determinations were calculated with the second method.

The stability of the different liposome-PT (L-PT) preparations in 0.9% NaCI solution at 4 0 C, and 50% human (AB) serum in 0.9% NaCl solution at 37 0 C was determined using the following formula: Stability at x hours EE at x hours x 100 EE at 0 hours The EE values used in the stability determinations were obtained by measuring PT in the supernatants by UV spectrophotometry NaCl solution) or x-ray 15 fluorescence (50% human AB serum). The stability in 0.9% NaCl solution was determined up to 14 days after the S" initial preparation. In addition, the L-PT preparations Y .were observed microscopically on day 14 to check the I morphology of the vesicles. The stability in 50% human AB serum was determined up to 18 hours after incubation.

Different cis-platinum analogues were encapsulated in multilamellar vesicles composed of DMPC:DMPG 7:3. The Sencapsulation efficiency for Pt-cyclopentenecarboxylato 1 25 racemic-DACH was 66%. The encapsulation efficiency was significantly increased when the pure trans RR DACH or trans-SS-DACH isomers were used (88% and 90%, respectively). The encapsulation efficiency for Pt-neodecanoato- S racemic-DACH, Pt-neodecanoato trans-RR-DACH, Pt-ndecyliminodiacetato racemic DACH complexes are presented in Table I, shown below.

A .i Sr 1 1 1 1 l r l ll 1 1 1 1 1 1 1 1 1 'n d i; i I-I -24- TABLE 1 ENCAPSULATION EFFICIENCY OF L-PT USING DIFFERENT ANALOGUES Platinum Analogue Encapsulation Efficiency .r e r ,r I It t.

Pt-cyclopentenecarboxylato racemic-DACH mixture Pt-cyclopentenecarboxylato trans-RR-DACH Pt-cyclopentenecarboxylato trans-SS-DACH Pt-neodecanoato-racemic DACH-mixture Pt-neodecanoato-trans-RR-DACH Pt-N-decyliminodiaceto-racemic- DACH mixture Pt-N-decyliminodiacetato-trans-RR-DACH .4

IE

r 44 r 4.

4. ft 4.c Co ftc 100 r' 41 1Mean of at least three experiments. Liposome composition DMPC:DMPG 7:3 Analogous experiments (not shown) with DMPC alone, DMPG alone, cholesterol alone, DMPC and DPMG combined in other concentrations, with or without cholesterol showed no better encapsulation efficiency and, most frequently, a significantly decreased EE.

i i r~nny EXAMPLE-7 Stability of L-PT in Aqueous Milieu Preparations were suspended in 0.9% saline and incubated at 4 0 C for 14 days. The liposome compositions were observed by light microscopy and the amount of free PT in the saline determined. Liposomes containing PT and composed of DMPG as the only phospholipid showed significant microscopica-I.y determined loss of structure.

Free PT was determined and stability was calculated as the percentage PT remaining in the liposomes. The results of these measurements are presented in Table 2 below.

:9915 TABLE 2 STABILITY OF L-PT IN $ALIAE L,-PT AT 14 DAYS 1 Platinum Analog Stability Pt-cyclopentenecarboxylato-racemic-DACH 89 Pt-cyclopentenecarboxylato-trans-RR-DACH 94 Pt-cyclopentenecarboxylato-trans-SS-DACH Pt -neodecanoa to-r acemic-DACH 100 Pt--neodecanoato-t rans-RR-DACH 99 P -iminodiacetato-racemic-DACH 100 *Pt-iminodiacetatlo-trans-RR-DACH 100 1Liposorne composition DMPC:DMPG 7:3 As may be seen in the above data, both the Pt cyclopentenecarboxylato trans-RR-DACH and the Ptneodecanoato-racemic-DACH exhibit greater stability than the Pt cyclopentenecarboxylato-,racendtc-DACH.

-26- EXAMPLE 8 Toxicity Studies of L-PT (Cyclopentenecarboxylato-racemic-DACH) Toxicology studies were carried out in 6-8 weeks old CD-1 Swiss mice weighing 22-25 gm and purchased from The University of Texas Science Park (Bastrop, TX). Free PT in suspension in hydroxypropylcellulose, DMPG, DMPG-PT, DMPC:DMPG 7:3 and DMPC:DMPC /:3-PT were administered intraperitoneally (ip) in volumes ranging between 0.1 and 0.3 ml. DMPC:DMPG 7:3-PT was also administered intravenously (iv) in one single injection or in 3 daily injections. The clinical behavior and the survival times 15 were monitored on a daily basis. The LD 10

LD

50 and LD 90 t 1 5 90 .64,06 were calculated considering the deaths occurring up to 14 sow$ days after injection.

t PT in suspension in hydroxypropylcellulose,

DMPG-PT

and DMPC:DMPG 7:3-PT had a similar LD 50 dose level when given in a single intraperitoneal (ip) injection (91 mg/kg, 86 mg/kg and 75 mg/kg respectively) (Table The amount of PT that would be encapsulated at the LD 50 dose level of empty liposomes composed of DMPG and DMPC:DMPG 7:3 was higher (183 mg/kg and >304 mg/kg respectively).

The LD 50 dose for DMPC:DMPG 7:3-PT injected iv was similar for the two schedules used: single injection and daily x 3 injections (82 mg/kg vs 96 mg/kg). Most deaths in both the ip and iv toxicity studies occurred between day 5 and 10 after injection. The results of these studies are presented in Table 3.

77 r. h~" -27- TABLE 3 TOXICITY OF DIFFERENT L-PT PREPARATIONS

(CYCLOPENTENECARBOXYLATO-RACEMIC-DACH)

ADMINISTERED IP AND IV 0 *04@ *0 0 0 .09 0 *a 9* 0 .r f r L-PT Route of LD10 LD50 Preparation Administration mg/kg mg/kg mg/kg Free PT ip x 1 61 91 125 DMPG-PT ip x 1 56 86 133 DMPC:DPMG 7:3-PT ip x 1 54 75 94 iv x 1 82 100 iv qd x 3 63 86 107 DMPG* ip x 1 158 183 228 DMPC:DMPG 7:3* ip x 1 >304 >304 >304 20 Results expressed encapsulated at the empty liposomes.

in mg/kg of PT

LD

10

LD

50 and that

LD

90 would be dose levels of EXAMPLE 9

NEPHROTOXICITY

trtr tt,& ,rr t g~m~ Blood urea nitrogen (BUN) was determined in samples obtained from the retroorbital plexus of CD 1 Swiss mice weighing 22-25 gm 96 hours after the ip injection (single dose) of CDDP, PT cyclopentenecarboxylato racemic DACH in hydroxypropylcellulose, DMPG-PT or DMPC:DMPG 7:3-PT at doses corresponding to the previously determined

LD

50 All L-PT preparations tested for toxicity were prepared under sterile conditions on the same day of the experiments. There were no significant BUN elevations 1 i i ii i 285i -28after the ip administration of the LD 50 dose of PT in suspension in hydroxypropylcellulose, DMPG-PT and DMPC:DMPG 7:3-PT (BUN at 96 hours 34.4 9.6 mg%, 30.0 4.6 mg% and 32.0 2.3 mg% respectively). The results are shown below in Table 4.

TABLE 4 ACUTE NEPHROTOXICITY OF CDDP, FREE PT (CYCLOPENTENECARBOXYLATO-RACEMIC-DACH) AND L-PT AT THE LD50 DOSE IN CD 1

MICE

50 q *r S

S

S

*4 r t

LD

50 Dose BUN at 96 hours 1 15 Preparation ip Single Injection (mg%) (mg/kg) CDDP 17 78.3 Free PT 91 34.4 9.6 DMPG-PT 86 30.0 4.6 DMPC:DMPG 7:3 75 32.0 2.3 1 Normal=27.2 mo% EXAMPLE In Vitro Antitumor Activity of Cyclopentenecarboxylato-Racemic- DACH-Pt Against L1210 Cells L1210 leukemic cells were grown in a suspension culture in McCoy's 5A medium (Gibco Laboratories, Grand Island, NY) supplemented with 10% horse serum, glutamine, streptomycin and penicillin at 37 0 C, 95% relative humidity in a 5% CO 2 atmosphere. Four ml of cell suspension were added to culture tubes and the appropriate concentration of free PT or L-PT was added (from 0.01 micro g/ml to ft ft cce tS

C

ft 4 -29micro g/ml final concentration). After 96 hours, the cell concentration of control and experimental cultures were calculated with a Coulter Counter (Coulter Electronics, Hialeah, FLA) and the percent inhibition calculated. The following preparations were tested: free PT, DMPG, DMPC:DMPG 7:3, DMPG-PT and DMPC:DMPG 7:3-PT. Results were a Iexpressed as the dose achieving a 50% growth inhibition

(ID

50 Results for empty liposomes were expressed as the amount of PT that would have been encapsulated at the ID 50 concentration.

The ID 50 for free cyclopentenecarboxylato-racemic 'DACH was 1.3 micro g/ml (Table Of the two L-PT preparations tested, DMPG-PT was slightly more active than 15 DMPC:DMPG 7:3-PT (mean ID 50 of three experiments; 0.7 and 1.6 micro g/ml respectively). Empty liposomes composed of DMPG had an ID 50 of 3.7 micro g/ml while the ID 50 for empty liposomes composed of DMPC:DMPG 7:3 was >10 micro g/ml (Table V t 0 A ll 14-.

'!I

TABLE IN VITRO ANTITUMOR ACTIVITY AGAINST L1210 CELLS OF FREE PT, L-PT AND EMPTY LIPOSOMES 1where PT is cvclopentenecarboxvlato-racemic-DACH-PT) g/ml) .0 Exp. 1 Exp. 2 Exp. 3 Mean Free PT 1.3 DM-PG-PT 0.7 1.0 1.4 0.7 DM4PG 2 3.0 3.0 5.0 3.7 .5 DMPC:DMPG 7:3-PT 1.9 2.0 0.9 1.6 DMPC:DMPG 7:3 2 >10.0 0* 4 4 4*4* 9.

*9 ft *9 I- 0 t ICDDP ID 0. micro g/ml 1 5 ID 50 expressed as micro g/ml of PT that encapsulated at the ID 50 concentration of would empty be liposomes.

I

t e V EXAMPLE 11 In Vivo Antitumor Activity of L-PT Against L1210 Mouse Leukemia where PT is cyclopentenecarboxylato-racemic-DACH t 91 t t C C The in vivo antitumor activity of CDDP, PT in hydroxypropylcellulose, DMPG, DMPG-PT, DMPC:DMPG 7:3, and DMPC:DMPG 7:3-PT was tested in an L1210-BDF 1 mouse model BDF 1 mice were purchased from Charles River (Wilmington, MA). Groups of 6-8 mice weighing 18-22 gm were inoculated ip with 1 x 10 6L1210 leukemia cells on day 0. L1210 cells were kept in DBA 2 mice were weekly passages between the different experiments. All L-PT preparations were injected ip in volumes of 0.1 to 0.3 ml 24 hours after tumor inoculation. Two different schedules A V- -31-

U

I trr r c; C C5 C C of administration were used: a single injection on day 1 or an injection on days 1, 5 and 9 (multiple). The doses of CDDP used were the ones that had resulted in a maximum antitumor activity in previous experiments. The doses of PT, DMPG-PT and DMPC:DMPG 7:3-PT used ranged from 3.125 mg/kg to 50 mg/kg (approximate LD 10 Clinical behavior and survival times.were monitored until all animals had died. Results were expressed as T/C (median survival time of treated mice/median survival time of control mice x 100) and number of long-term survivors. Mice living more than 30 days and more than 60 days were considered to be long-term survivors for the single and multiple injection schedule respectively. All L-PT preparations tested for antitumor activity were prepared under sterile 15 conditions on the same day of the experiment. In the first set of experiments, the effect of a single ip dose of CDDP, free PT, DMPG-PT and DMPC:DMPG 7:3-PT in the treatment of L1210 leukemia was tested. Mice treated with free PT at doses of 12.5 mg/kg and 25 mg/kg had a T/C comparable to those treated with 10 mg/kg of CDDP (162 vs 178, means of three experiments) (Table DMPG-PT at doses of 12.5 mg/kg, 6.25 mg/kg and 3.125 mg/kg had an antitumor activity comparable to free PT and CDDP (mean T/C=175 for 12.5 mg/kg; 158 for 6.25 mg/kg; and 163 for 25 3.125 mg/kg) (Table Doses of DMPG-PT of 25 mg/kg or more were toxic for L1210 leukemia-bearing BDF 1 mice.

Mice treated with DMPC:DMPG 7:3-PT at doses of 25 mg/kg, 12.5 mg/kg and 6.25 mg/kg had a similar or slightly higher T/C than those obtained with CDDP, free PT and DMPG-PT (mean: T/C=215 for 25 mg/kg; 178 for 12.5 mg/kg; and 200 for 6.25 mg/kg) (Table DMPC:DMPG 7:3-PT at a dose of mg/kg was toxic for L1210 leukemia-bearing BDF 1 mice.

Empty liposomes composed of DMPG and DMPC:DMPG 7:3, at doses equivalent to the optimal ones of loaded vesicles 35 (L-PT) did not shown antitumor activity T/C=105 for DMPG and 93 for DMPC:DMPG Lon,-term survivors (one

ECCC

C C C!~li Si i 1 C 4 1B I i.\ 4 AL1 4 4 4' V TT S-32or two mice of six) were seen in the groups treated with CDDP, DMPG-PT and DMPC:DMPG 7:3-PT (Table 6).

In the experiment using a multiple dose schedule, the highest T/C obtained was 253 for CDDP 7.5 mg/kg x 3, 284 for free PT 12.5 mg/kg x 3, 179 for DMPG-PT 6.25 mg/kg x 3 and 403 for DMPC:DMPG 7:3-PT 12.5 mg/kg x 3. Long-term survivors (1 of 6 mice) were only observed in the group treated with DMPC:DMPG 7:3-PT (Table 7).

r X t V *C o 0c *14* r t t tL I IC I I I I

:I

i:: .<6res~4.

described in Example 2, was dissolved in 10 ml of H 2 0.

V

1 77 f4h 33 TABLE 6 IN VIVO ANTITUMOR ACTIVITY AGAINST MOUSE L1210 LEUKEMIA OF CDDP, FREE PT AND L-PT ADMINISTERED IP (DAY 1) where PT is cvclo~entenecarboxvlato-racemic-DACH C. 0 00 #0 9 0 f~

C

I- t*0

~*L

C El

I,,

S4~

I~

04 4 ti IE~ A 0

LA

f A tLL~ 4 I

T/C

Group (Number of Survivors on Day Number Preparation 4 Exp.1 1 Exp.2 2 Exp. 3 3 1 CDDP 10 mg/kg 167 189 (1/6) 2 Free PT 25 mg/kg 168 3 12.5 mg/kg 173 136 179 4 DMPG-PT 25 mg/kg 100 12.5 mg/kg 160 209 158 6 6.25 mg/kg 158 7 3.12 mg/kg 163 (2/6) 8 DMPC:DMPG 7:3-PT 25 mg/kg 213 200 232 (1/6) 9 12.5 mg/kg 167 189 (1/6) 6.25 mg/kg 200 1 2 3 4 median survival of control 7.5 days median survival of control 11 days median survival of control 9 days All preparations were injected ip in 0.1-0.3 ml 24 hours after the ip inoculation of 1 x 10 6 L1210 cells.

A 1

A

-34- TABLE 7 IN VIVO ANTITUMOR ACTIVITY AGAINST MOUSE L1210 LEUKEMIA OF CDDP, FREE PT AND L-PT ADMINISTERED IP (DAYS 1, 5 and 9) WHERE PT IS CYCLOPENTENECARBOXYLATO-RACEMIC-DACH

T/C

(Number of Survivors Group Number Preparation 1 Dose on Day ft Ot~ p B UP

B

C

a--tB (ft aft a ~tB~I at, B S a *i Bft

I

A I-I

'I

B

CCI

IA

I tt* It I- C I

L

-IA( I L t

C.

IC 15 1 2 3 4 6 7 8 9 10 25 11

CDDP

Free PT

DMPG-PT

DMPC:DMPG 7:3-PT 7.5 25 12.5 6.25 12.5 6.25 3.12 1.56 12.5 6.25 3.125 mg/kg mg/kg mg/kg mg/kg mg/kg mg/kg mg/kg mg/kg mg/kg mg/kg mg/kg 253 158 284 168 105 179 168 115 403 253 210 (1/6) (1/6) All preparations were injected ip in volumes of 0.1 to 0.3 ml 24 hours, 5 days and 9 days after tumor inoculation EXAMPLE 12 In Vivo Antitumor Activity of Different L-PT Analogs Against L-1210 Leukemia The antitumor activity against L-1210 murine leukemia of the different L-PT analogs was assessed in an .4 .r L-1210-BDF, mouse model (tumor inoculation day 0, treatment day 1, ip) as described earlier herein.

Compared with CDDP T/C=175), the L-PT analogues showed equivalent or slightly higher anti-tumor activity, with the exceptions of L-PT (cyclopentenecarboxylato trans-SS- DACH 155 and N-decyliminodiaceto racemic-DACH 150 and N-decyliminodfacetato trans-RR-DACH 162). These results are shown in Table 8.

TABLE 8 o *q a 0 *o a 00 000* *6 t

C

S (C S C C C

ANTIUM,

3 EFFECT AGAINST L1210 LEUKEMIA OF CIS-PLATINUM AND 1 DIFFERENT LIPOSOMAL-PLATINUM, ANALOGUES 1 Platinum Analog Dose 4 mg/kg T/C 2 C Ct C CCC C

C

PT-cyclopenteneca rboxylatoracemi c-DACH PT-cyclopentenecarboxylatot rans-RR-DACH PT-cyclopentenecarboxylatotrans-SS-DACH PT-neodecanoato- racemic-DACH 213 187 155 187 t -36- PT-neodecanoato-trans-RR-DACH 25 175 PT-N-decyliminodiacetato-racemic-DACH 25 150 PT-N-decyliminodiacetato trans-RR-DACH 25 162 Cis-platinum (CDDP) 5 10 175 1 Liposome composition DMPC:DMPG 7:3 2 Median survival of treated mice Median survival of control mice x00 3 1 x 106 L1210 cells inoculated ip on day 0.

eC 4 Treatment ip on day 1 C l C c 5 Dissolved in saline, 1 mg/ml EXAMPLE 13 In Vivo Antitumor Activity of L-PT-NEODECANOATOt RACEMIC-DACH Against Liver Metastases of Mouse M5076 Reticulosarcoma The potential antitumor effect of L-PT against liver metastases was tested using L-PT-NEODECANOATO-RACEMIC-DACH prepared as described in Example 6 and the mouse M5076 reticulosarcoma, which is a tumor that metastasizes exclusively to the liver.

L-PT-NEODECANOATO-RACEMIC-DACH was more active than cis-platinum in the treatment of established liver metastases of M5076 using two different tumor inocula and schedules of administration (Table 9 and 10). L-PT- NEODECANOATO-RACEMIC-DACH (25 mg/kg on days, 8, 12, 16) resulted in a more than two fold reduction in the number

JA,

Jet ev -37of liver metastases compared with cis-platinum (7.5 mg/kg on days, 8, 12, 16) on day 30 after the intravenous inoculation of 105 M5076 cells (mean number of liver metastases SD 39 21 for L-PT vs 114 38 for cisplatinum (Table L-PT-NEODECANOATO-RACEMIC-DACH mg/kg on days 4, 8, 12) resulted in the complete inhibition of liver metastases of M5076 on day 45 after the inoculation of 104 M5076 cells, while 4/6 animals treated with cis-platinum (7.5 mg/kg on days 4, 8, 12) had 175 or more liver metastases (Table L-PT-NEODECANOATO-RACEMIC-DACH was effective in the S prophylaxis of liver metastases of M5076 reticulosarcoma.

L-PT-NEODECANOATO-RACEMIC-DACH (37.5 mg/kg on day -1) resulted in a five-fold decrease in the number of liver S" metastases on day 21 after the intravenous inoculation of 4 I 104 M5076 cells (inoculation day 0) compared with cisplatinum (10 mg/kg on day and untreated animals (mean number of liver metastases SD 52 20 for L-PT, 256 54 for cis-platinum, and 226 21 for control) (Table 11).

r Cr t t 77

L

I 1J--- 9 -38- TABLE 9 Treatment of Liver Metastases of M5076 Reticulosarcoma with L-PT-NEODECANOATO-RACEMIC-DACH Dose Schedule No. Liver Metastases on Day Treatment mg/kg day mean SD Cis-platinum 7.5 8,12,16 114 38 15 L-PT-NEODECANOATO- 25 8,12,16 39 21

RACEMIC-DACH

*Groups of 10 C57BL/6 mice were inoculated on day 0 with 5 M5076 cells intravenously. Animals were treated on 20 days 8, 12, and 16 with cis-platinum or L-PT- NEODECANOATO-RACEMIC-DACH. The median survival of untreated animals was 19 days. Treated animals were sacrificed on day 30, the livers dissected, placed in Bouin's fixative, and the number of liver-tumor colonies counted.

Ett 9.C 9. C C C C

C

r~r~ i A c .4i 77k 'P7 tP" 4! r A r -39- TABLE Treatment of Liver Metastases of M5076 Reticulosarcoma with L-PT-NEODECANQATO-RACEMIC-DACH Dose Schedule N4o. Liver Metastases on Day Treatment mg/kg day mean SD Cis-platinum 7.5 24r8,12 0,011751>2001>200,>200 L-PT-NPODECANOATO- 25 4,8,12 0,0,0,0,0,1

RACEMIC-DACH

*Groups of 6 C57BL/6 mice were inoculated on day 0 with 4 M5076 cells intravenously. Animals were treated on 20 days 4, 8, and 12 with cis-platinum or L-PT-NEODVCANOATQ- RACEMIC-DACH. The median survivel of untreated animals was 30 days. Treated animals were sacrificed on day the livers dissected, placed in Bouin's fixative, and the number of liver-tumor colonies counted. Two of the anImals treated with cis-platinum died before day versus none in the grovcp treated with L-PT.

'4

II

~t4 I 44 Ii I *4 Ii 4 4* A 'A

I

49*44* 4 4 444,44 4

II

Q

1 TABLE 11 a.

a.

I

I II I It Prophylaxis of Liver Metastases of M5076 Reticulosarcoma with L-PT-NEODECANOATO-RACEMIC-DACH Dos~e Schedule No. Liver Metastases on Day 21 Treatment mg/kg day mean SD None 226 21 Cis-platinum 10 1 256 54 L-PT-NEQDECANOATO- 37.5 1 52

RACEMIC-DACH

20 *Groups of 6 C57BL/6 mice were treated on day 1 with cis-platinum or L-PT Neodecanoato- Racemic-DACH. Animals were inoculated on day 0 with 10O 4 M5076 cells intravenously. The median survival of untreated animals was 21 days. Treated animals were sacrifi.ced on day 21, the livers dissected, placed in Bouin's fixatIve, and the number of tumor colonies counted.

I

11 Sec 77 4 -41- EXAMPLE 14 Preparation of cis-bis-neodecanoatocis-diamine-platinum (II).

Cis-diamine-diiodo-platinum (II) (NH 3 2 Pt-I 2 was first prepared by the following method:

K

2 PtC1 4 (5g) was dissolved in water (20ml). An aqueous solution of KI (3g) was added and a dark brown solution was obtained. Aqueous concentrated ammonia (2ml) was added to the mixture which was stirred for 2-3 hr. at room y. temperature. The mixture was filtered and the solid was Swashed with an excess of water, ethanol and ether. The 15 product was dried over P 2 0 5 under vacuum. Yield The compound according to the invention was then prepared as follows:

(NH

3 2 -Pt-I 2 (1.0g) was suspended in water and aqueous solutions of AgNO 3 (0.68g 20ml H 2 0) was added thereto. The reaction mixture was stirred overnight at room temperature in the dark. The AgI precipitate was filtered and filtrate was concentrated by rotary Sevaporation. To the concentrated solution a solution of S, sodium neodecanoato prepared in situ, (neodecanoic acid S 0.688g in 20ml methanol and IN NaOH, 4ml) was added. The reaction mixture was stirred overnight at room temperature. The yellow reaction mixture was evaporated to dryness at 40 0 C under reduced pressure using a rotary evaporator. A gummy product was obtained which was extracted in chloroform and the chloroform extract was dried over anhydrous MgSO 4 MgSO 4 was separated by filtration and filtrate was evaporated to dryness under reduced pressure using a rotary evaporator. A cream-color r h 1 7i p-.i 4 '4 -42solid was obtained which was dried over P 2 0 5 in vacuo.

The final product was stored at 0°C.

The elemental analysis of the final product was C41.58, H8.03; N 4.45%. The calculated values for

C

20

H

44

N

24 Pt. is C42.00; H7.7, N4.90%.

The structural formula of the cis-bis-neodecanoatobis-diamine-platinum is as follows: wr (H 3

N]

2 Pt [OC CRRR where R, R" can be CH 3

C

2

H

5 or C 3

H

7 to give a carboxylato radical function with C 10

H

19 0 2 (MW 171) as empirical formula.

Cis-bis-neodecanoato-bis-diamine-platinum (II) is highly soluble in chloroform, methanol and other common organic solvents, but insoluble in water.

EXAMPLE Preparation of cis-bis-neodecanoato-bis cyclohexylamine-platinum (II) dihydrate The method of Example 14 was followed, using the cyclohexylamine ligand in place of ammonia. The complex is highly soluble in chloroform, methanol and other organic solvents, but insoluble in water.

Elemental Analysis; Calculated for C 32

H

64

N

2 0 4 .2H 2 0, C49.71; H8.80, N3.62%, found C49.31; H8.39; N3.16% The structural formula of the cis-bis-neodecanoatobis-cyclohexylamine-platinum (II) is as follows: i 4 I J ~rc -43-

[C

6

H

11

NH

2 2 Pt [OOC-C-R'RR"] 2 where R, R" can be CH 3

C

2

H

5 or C 3

H

7 to give a carboxylato radical functions C 10

H

19 0 2 (MW 171) as empirical formula.

EXMPLE 16 Preparation of cis-bis-neodecanoatoethylenediamine-platinum (II) Cis-diiodo-ethylenediamine-platinum was first prepared by the method of Example I, using ethylenediamine J 4 ligand in place of ammonia and with a 96% yield of product.

Sulfato-ethylenediamine-platinum

H

2 0 was prepared by the following method.

20 Cis-bis-diiodo-ethylenediamine-platinum (3.9) J was suspended in 10ml H 2 0 and an aqueous solutions of C Ag 2

SO

4 (2.2g in 200 ml H 2 0) was added thereto. The tt t reaction mixture was stirred in the dark overnight at room temperature. AgI was removed by filtration and the yellow filtrate was evaporated to dryness at 40-45 0 C under reduced pressure using rotary evaporation. The final product was dried over P 2 0 5 under vacuum. The product S' yield was 2.35g The compound according to the invention was then prepared as follows: i Sulfato-ethylenediamine-pl] :ium H 2 0 (0.369 g) o was dissolved in H 2 0 (20ml) and a solution of sodium neodecanoato prepared in situ (neodecanoic acid, 0.344g in ml methanol and IN NaOH, 2ml) was added thereto. The L 77 S. rs! lit. s -44reaction mixture was stirred for 2-3 hr. at room temperature. The reaction mixture was evaporated to dryness at 40-45 0 C under reduced pressure using rotary evaporation. A gummy product was obtained which was extracted in chloroform and the chloroform extract was dried over anhydrous MgSO 4 The MgSO 4 was separated by filtration and the filtrate was evaporated to dryness under reduced pressure using a rotary evaporator. The final product was dried over P 2 0 5 in vacuo. The product was stored at O.C.

Elemental analysis; calculated for C 22

H

46

N

2 04Pt. H 2 0, C42.86; H7.79; N 4.54%, found C43.07; H 7.32; N 4.71%.

15 Cis-bis-neodecanoato-ethylenediamine-platinum (II) is highly soluble in chloroform, methanol and other organic solvents, but insoluble in water.

The structural formula of the cis-bis-neodecanoatoethylenediamine-platinum (II) is as follows:

CH

2 NH 2 *4 9 .4.9 9* 9 4 *i 9 *i 9 11 *e 9 I C I

CH

2 NH 2 Pt [OOC-C-R'RR"], where R, R" can be CH 3

C

2

H

5 or C 3

H

7 to give a carboxylato radical function C 10

H

19 0 2 (MW 171) as empirical formula.

(CI 51c 77^

I~

IJ

EXAMPLE 17 Preparation of cis-bis-neodecanoatobis-isopropylamine-platinum (II) Cis-bis-neodecanoato-bis-isopropylamine-platinum (II) and sulfato-bis-isopropylamineplatinum (II) were first prepared by the method of Example 16, using isopropylamine ligand in place of ethylenediamine.

I

SThe compound according to the invention was then prepared as follows: Sulfato-bis-isopropylamine-platinum H 2 0 (0.427g) was dissolved in H 2 0 (50ml) and a solution of sodium-neodecanoato prepared in situ (neodecanoic acid 0.344g in 20 ml of methanol and 1N NaOH, 2 ml) was added thereto. The reaction mixture was stirred for 2-3 hr. at 20 room tempeature. The reaction mixture was evaporated to S dryness at 40-45 0 C under reduced pressure using rotary C evaporator. A gummy mass was obtained which was extracted in chloroform and the chloroform extract was dried over anhydrous MgSO 4 The MgSO 4 was separated by filtration and filtrate was evaporated to dryness under reduced pressure using a rotary evaporator. The product was dried Sover P 2 0 5 in vacuo. The final product was stored at OOC.

Elemental analysis, calculated for C 26

H

56

N

2 0 4 Pt, C47.63; H8.53; N4.26%; found C 47.74; H8.47; N 3.93%.

The structural formula of the cis-bis-neodecanoatobis-isopropylamine-platinum (II) is as follows: I -46-

([H

3

C]

2

CH-NH

2 2 Pt [OOC-C-R'RR"] 2 where R, R" can be CH 3

C

2

H

5 or C 3

H

7 to giv a carboxylato radical function with C 10

H

19 0 2 (MW 171) as an empirical formula.

Cis-bis-neodecanoato-bis-isopropylamine-platinum is highly soluble in chloroform, methanol and other organic solvents, but insoluble in water.

EXAMPLE 18 4U Preparation of cis-bis-decanoato-trans- R,R-1,2-diaminocyclohexane-platinum II.

SSulfato-trans-R,R-l,2-diaminocyclohexane-platinum II

H

2 0 (0.423g) was dissolved in H 2 0 (20ml) and a solution of sodium-decanoato prepared in situ (0.344g decanoic acid in methanol and lN NaOH 2ml) was added thereto. The I e "20 reaction mixture was stirred for 2-3 hr. at room temperature. The reaction mixture was evaporated to dryness at 40-45 0 C under reduced pressure using a rotary evaporator. A solid was obtained which was extracted in chloroform and chloroform extract was dried over anhydrous MgSO 4 The MgSO 4 was removed by filtration and filtrate was evaporated to dryness under reduced pressure using rotary evaporator. The product was dried over P205 in vacuo. The final product was stored at OOC.

Elemental analysis calculated for C 26

H

52

N

2 04Pt.H 2 0 C46.59; H8.06; N 4.18%, found C 45.94; H7.87 N 4.31%.

Cis-bis-decanoato-trans-R,R-l,2-diaminocyclohexaneplatinum II is highly soluble in chloroform and other organic solvents, but insoluble in water.

w l "i j' r- ;;r ?.i :i i i -47- The structural formula of the cis-bis-decanoatotrans-R,R-l,2-diaminocyclohexane-platinum II is as follows:

SNH

2 /i NH 2 PT [OOC (CH 2 8

CH

3 2 C t C 4C EXAMPLE 19 Cis-bis-neopentanoato-trans-R,R-l, 2-diaminocyclohexane-platinum II.

r Cr

AP,

Sulfato-trans-R,R-l,2-diaminocyclohexane-platinum

II.

H

2 0 (0.423g) was dissolved in water (20ml) and a solution of barium-neopentanoato prepared in situ (neopentanoic acid, 0.204g, in 5 ml of methanol and Ba (OH) 2 .8H 2 0 0.3g in 50 ml H 2 0 combined together) was added thereto. The reaction mixture was stirred for 2-3 hr. at room temperature. The reaction mixture was evaporated to dryness at 40-45 0 C under reduced pressure using a rotary evaporator. The residue was extracted with methanol, filtered and the filtrate was evaporated to dryness. A solid was obtained which was further extracted with chloroform. The chloroform extract was evaporated to dryness and a cream-color product was obtained. The product was dried over P 2 0 5 under vacuum.

Elemental analysis calculated for C 6

H

32

N

2 04Pt.2H 2 0; C35.00; H6.57; N5.11%, found C35.16; H6.17; N5.27%.

I

.74 .1* -48- Cis-bis-Neopentanoato-trans-R,R-1,2-diaminocyclohexane-platinum II, is highly soluble in chloroform, methanol and other common organic solvents.

The structural formula of the cis-bis-neopentanoatotrans-R,R-l,2-diaminocyclohexane-platinum II is as follows:

NH

2 Pt

OOC-C-(CH

3 3 2 It f LI EXAMPLE Encapsulation efficiency and antitumor activity of lipophilic cisplatin analogs

I

I

II±11 20 The compounds prepared in Examples 14-19 were tested for their efficiency of encapulation in liposomes by the methods described in Example 6. These liposomeencapsulated compounds were tested to determine their optimal dose and effectiveness as inhibitors of in vivo tumor growth as described in Example 12. The data in Table 12 reveal the resultant measurements.

;r

I

t i.

Table 12 Encapsulation Efficiency and Antitumor Activity of Lipophilic Cisplatin Analogues Incorporated in Liposomes Compound Encapsulation Optimal %T/C Efficiency dose L1210 ip/ip mg/kg single dose Cis-bis-neodecanoato-cis-diamine-platinum (11) 95% 50 200 Cis-bis-neodecanoato--bis-cyclohexylamine-platinum (11) 89% 100 125 Cis-bis-neodecanoato-ethylenediamine-platinum (11) 82% 75 144 Cis-bis-neodecanoato-bis-isopropylamine-platinum (11) 87% 100 150 Cis-bis--decanoato-trans-R,R-l, 2-diaminocyclohexane-platinum (II) 96% 50 187 Cis-bis-neopentanoato-trans-R,R-l,2-diaminocyclohexane-platinum (11) 93% 25 170 a w C a C C C a 96 La a 66 696 96 n 7' ri, liliL

J

I

EXAMPLE 21 In Vitro cytotoxicity against human malignant cell lines .r a: r C

C

4

C

C C Cc

C

st C..

C

Cis-bis-neodecanoato-1,2-diaminocyclohexane platinum (II) was tested in the liposomal-form against three human malignant cell lines of colon carcinoma (LoVo, SW620, and SW403) using a colony formation inhibition assay. The drug concentration that resulted in a 50% inhibition of colony formation (IC50) ranged from 4 to 8 uM. The of cisplatinum for these same cell lines ranged from 3 to 7 uM.

xxxxx x x xxx Changes may be made in the various compositions, elements, steps and procedures described herein without departure from the concept and scope of the invention as defined in the following claims.

i "ai

Claims (110)

1. A platinum (II) four-coordinate complex having the formula: Pt Pt (II) o 00 a a a 005 0 tr wherein R 1 and R 2 are each carboxylato bearing a hydrophobic radical function or, when linked together, are a dicarboxylato bearing a hydrophobic radical function, and wherein R 3 and R 4 are each: H I -N R H C I r CC c c wherein R 5 is selected from the group consisting of hydrogen,alkyl, aryl, aralkyl, alkenyl, or cycloalkyl, cycloalkenyl or a combination thereof; or wherein R 3 and R 4 when linked together, are selected from the group consisting of cycloalkyl-l,2-diamino having between about 3 and 7 carbon atoms, and alkyl-l,2-diamino having between about 2 and 12 carbon atoms; and Ii~i~ S r r FRIDAY y, R a 1987 said complex is defined further as being substantially soluble in methanol or chloroform and substantially inso1ible in water.

2. The complex of claim 1 wherein R3and R 4 Lare defined further as rampi noan alkyl having between 1 and carbon atoms or cycloalky. having between 3 and 12 carbon atoms, The complex of claim 2 wherein Ris an alkyl having between 1 anid 20 carbon atoms. The complex of claim 2 wherein the alkyl has between 6 and 12 carbon atom. 20 5. The complex of claim 2 wherein the alkyl is defined 99 further as having between about 2 and 6 carbon atoms.

6. The complex of claim I wherein the ca.rboxylato is an alkylcarboxylato having between about 5 and 20 carbon .9 A atoms, or an arylcarboxylato wherein aryl. is phevwyl, naphthyl, or alkylphenyl wherein the alkyiphenyl has between about 12 and 16 carbon atoms. 309 Toshen complex of claim 1 wherein the dicarboxylato is aalkyldicarboxylato having between about 5 and 20 carbon atosanaryldicarboxylato wherein aryl is naphthyl, phenyl, or alkyiphenyl wherein the alkylphenyl has between about 6 and 12 carbon atoms. W2~ jI jI i re FRIDAY, -6 FEB 1i8? -53-

8. The complex of claim 7 wherein the aryl is defined further as having between about 6 and 14 carbon atoms.

9. The complex of claim wherein the alkenyl is defined further as having between about 5 and 20 carbon atoms. The complex of claim 1 wheein the cycloalkyl is defined further as having between about 3 and 12 carbon atoms. 9 9 9. 9 9 *999 91 S t *I e 9 c, 'it-

11. The complex of claim 3 wherein R 1 and R 2 are cycloalkenyl carboxylato, the cycloalkenyl having between about 5 and 20 carbon atoms, and wherein R 3 and R 4 are linked together and are trans-S,S or-R,R-1,2- diaminocyclohexane when the cycloalkenyl has 6 or less carbon atoms.

12. The complex of claim 1 wherein the aralkyl is defined further as containing linked aryl and alkyl portions and having between about 7 and 20 carbon atoms. 4 9't **9 .9 i. 3

13. The complex of claim 12 wherein the aryl portion has between about 6 and 10 carbon atoms.

14. The complex of claim 12 wherein the alkyl portion has between about 1 and i carbon, atoms.

15. The complex of claim 1 wherein r 3 and R 4 taken together are cycloalkyl-l,2-diamino, have between about 3 I- i t ii. i 54 and 20 carbon atoms, and wherein the cycloalkyl ring has between about 3 and 12 carbon atoms.

16. The complex of claim 15 wherein the 1,2- diaruinocyclohexane is trans-R,R-l, 2 -diaminocyclohexane, and Rland R2are each decanoato which are g". I17. The complex of claim 16 wherein Rl and R 2 are neodecanoato of the formula R wherein R, R I and R'I are -methyl, ethyl, propyl, *and the sum of the carbon atoms of R, and is 8.

18. The complex.'of claim 1. wherein Rand R linked 1 1.2 S together, are a dicarboxylato of the formula: R7 OOC -CH NR R8 wherein R*is alkyl having between about 10 and carbon atoms and R and R 8 are each hydrogen or an alkyl having betw~een about 1 and 5 carbon atoms.

19. The complex of claim 18 wherein nRand Rareeach QIN hydrogen. 7 Dr.> r j h1<IUAY, -6 FEB 198? The complex of claim 18 wherein the aycloalkyl-1,2- diamino is 1,2-diaminocyclohexane.

21. The complex of claim 20 wherein the 1,2- diaminocyclohexane is defined further as being trans-R,R- 1,2-diaminocyclohexane or trans-S,S-l,2- diaminocyclohexane.

22. The complex of claim 21 wherein R 6 is defined further as being decyl. ,q C C a. a, a a a. C C C~4 C a 4* a. a C *4 1 15 23. The complex of claim 21 wherein R 6 is decyl, R 7 and R 8 are hydrogen, and the dicarboxylato is cis.

24. The complex of claim 18 whereinR7 hydrogen, and the dicarboxylato is gl. and R8are The complex hydrogen. of claim 18 wherein R7a nd R 8 are

26. The complex further as being of claim 16 wherein R1and R2are defined neo-pentoato, III

27. The complex 2il. of claim 18 wherein the dicarboxylato is

28. The complex of claim 18 wherein the 1,2- diaiiinocyclohexane is in the R,R conformation. V 1' 1, 56

29. The complex of claim 1 wherein R5is hydrogen. A 30. The complex of claim 29 wherein R1and R 2 are each an alkylcarboxylato.

31. The complex of claim 30 wherein the alkylcarboxylato is neo-decanoato of the formula R ii OOC C R and wherein R, and are methyl, ethyl, or propyl, and the sum of the carbon atoms of R, RI, and is 8.

32. The complex of claim 12 wherein R 1 and R2are g"j.

33. The complex of claim 1 wherein R3and R4are unlinked and are each: H where R 5 is cyclohexyl.

34. The complex of claim 33 wherein R1and R2are each alkylcarboxylato. The complex of claim 33 wherein Rl and R 2 are -ach neo-decanoato of the formula oOCC R q R Cc'~ and wherein the propyl, and the and is 8.

36. The complex R, and are methyl, ethyl, or sum of the carbon atoms of R, R', of claim 33 wherein R I and R2are g" of claim 1 wherein R 3 and R4are unlinked

37. and The complex are each: N R H wherein R 5is isopropyl. 69 9. S *99* S. S S S. S S 9* *5 I S *1S9 *4 S. S 5* S S# 9. S 4** '44. S

38. The complex of claim 37 wherein Rl and R 2 are each neo-decanoato of the formula R 000 C- R and wherein the R, and are methyl, ethyl, or propyl, and the sum of the carbon atoms of R, and is 8.

39. The complex of claim 37 wherein R1and R 2 i.re gjgz.

40. The complex of claim and are alkyl-1,2-diamino 1 wherein R3and R4are linked having 2 to 12 carbon atoms.

41. The complex of claim 40 wherein the alkyl is ethyl. Ozll

42. The complex of claim alkylcar boxylato. 41 wherein R1and R2are z~V 57a

43. The complex of claim 42 wherein the alkylcarboxvlato is neo-decanoato of the formula R 00C C R and wherein R, and R' are methyl, ethyl, or propyl, and the sum of the carbon atoms of R, R' and is 8. eq C 4~ CC C eC C C CC. C C@ C C C. C I lit I it It t 41 *s KU 44 cc FRIDAY, -6 FEB 1987 -58- A liposome comprising a four-coordinate platinum )mplex having the formula: Pt (II) R 2 ?9 4 9 9r *t S( ttI; I tI wherein R 1 and R 2 are each carboxylato bearing a hydrophobic radical function or when linked together are a dicarboxylato bearing a hydrophobic radical function, and wherein R 3 and R 4 are each: H N R H I r and R 5 is hydrogen, alkyl having carbon atoms, or cycloalkyl having carbon atoms; between about 1 and between about 3 and 1* or wherein R 3 amd R 4 when linked together are cycloalkyl-l,2-diamino having between about 3 and 7 carbon atoms, or alkenyl-l,2-diamino having between about 2 and 12 carbon atoms; and said complex is defined further as being substantially soluble in methanol or chloroform and substantially insoluble in water, and a phospholipid. I 1_ II~. I I FRIDAY, -6 FFB 1987 -59- A pharmaceutical composition comprising the liposome of claim 44 and a pharmaceutically acceptable carrier or diluent.

46. The liposome of claim 44 wherein R 5 is an alkyl having between about 6 and 12 carbon atoms. 1C 0 *4 fa ~it

47. The liposome of claim 44 wherein the carboxylato is an alkylcarboxylato having between about 5 and 20 carbon atoms, or an arylcarboxylato wherein aryl is naphthyl, phenyl, or an alkylphenyl wherein the alkylphenyl has between about 12 and 16 carbon atoms.

48. The lipo3ome of claim 44 wherein the dicarboxylato is an alkylcarboxylato having between about 5 and 20 carbon atoms, or an arylcarboxylato wherein aryl is naphthyl, phenyl, or alkylphenyl, wherein the alkylphenyl has between about 12 and 18 carbon atoms.

49. The liposome of claim 44 wherein each hydrophobic radical function is defined further as being alkyl, aryl, aralkyl, alkenyl, or cycloalkyl, cycloalkenyl or a combination thereof,

50. The liposome of claim 49 wherein the complex is cis- bis-n-decyliminodiacetato-trans-RR-1,2- diaminocyclohexane-platinum (II). ii (j b ii i i -L -ii i U FRIDAY, -6 FEB 1987

51. The liposome of claim 44 wherein the complex is cis- bis-n-decyliminodiacetato-trans-RR-1,2- diaminocyclohexane-platinum

52. The liposome of claim 44 wherein the complex is cis- bis-neodecanoato-Trans R,R-1,2-diaminocyclohexane-platinum (II). 0 00 *0 *r 0 0 0 *0 t or 0 *r a I (I

53. The liposome of claim 44 wherein the complex is cis- bis-ammine-bis-neodecanoato-platinum (II).

54. The liposome of claim 44 wherein the complex is cis- bis-decanoato-trans-R,R-l,2-diaminocyclohexane-platinum (II),

55. The liposome of claim 44 wherein the complex is cis- bis-neopentanoato-1, 2-diaminocyclohexane-platinum (II). I It 4- C 14-It 4 i

56. The liposome of claim 44 wherein the complex is cis- bis-cyclopentenecarboxylato-trans-R,R-1,2- diaminocyclohexane-platinum (II).

57. The liposome of claim 44 wherein the complex is cis- bis-neodecanoato-ethylenediamine-platinum (II).

58. The liposome of claim 44 wherein the complex is cis- bis-neodecanoato-bis-isopropylamine-platinum (II). ik '-Ii P1 L I FRIDAY, -6 FEB Io9 -61-

59. The liposome of claim 44 wherein the complex is cis- bis-decanoato-trans-R,R-1,2-diaminocyclohexane-platinum (II). The liposome of claim 44 wherein the complex is cis- bis-neopentanoato-trans-R,R-l,2-diaminocyclohexane- platinum (II).

61. The liposome of claim.44 wherein the complex is cis- bis-neodecanoato-bis-cyclohexylamine-platinum (II). o *0 S 0*40 t C 15 62. The liposome of claim 44 wherein the phospholipid is defined further as being phosphatidylglycerol, phosphatidylcholine, sphingomyelin, phosphatidic acid or phosphatidylserine. U..

63. The liposome of claim 44 wherein the phospholipid is defined further as consisting essentially of phosphatidyl- glycerol, a phosphatidylcholine or a combination thereof.

64. The liposome of claim 44 defined further as comprising cholesterol.

65. The liposome of claim 63 wherein the phosphatidyl- glycerol is defined further as consisting essentially of dimyristoylphosphatidylglycerol and the phosphatidyl- choline is defined further as consisting essentially of dimyristoylphosphatidylcholine. li i i -ii- ti 1 i 1 I" i t r -NILUAY, -6 FEB 1987 -62-

66. The liposome of claim 65 wherein the dimyristoylphos- phatidylglycerol and the dimyristoylphosphatidylcholine are defined further as being in a ratio between about 1 to and 10 to 1.

67. The liposome of claim 65 wherein the dimyristoylphos- phatidylglycerol and the dimyristoylphosphatidylcholine are defined further as being in a ratio of about 3 to 7.

68. The liposome of claim 44 defined further wherein the platinum complex and the phospholipid are in a ratio between about 1 to 10 and about 1 to 00 *a 0 o e 0 00* r C C Ce

69. The liposome of claim 44 defined further wherein the platinum complex and the phospholipid are in a ratio between about 1 to The liposome of claim 44 defined further as being multilamellar. f E C C t c C t C t, t

71. The liposome of claim 44 defined further as being unilamellar.

72. A method of treating an animal afflicted with tumor cells sensitive to a platinum (II) four-coordinate complex which comprises administering a liposome to the animal, said liposome comprising a phospholipid and a platinum (II) four-coordinate complex having the formula: ii I r r ri i 1 4-. 'UI r r 2~c~ FRID Ay 6 FEB 198? -63- R 3 I Pt (II) 5R4 R2 wherein R1and R2are each carboxyliato bearing a hydrophobic radical function or when linked together are a dicarboxylato bearing a hydrophobic radical function, and wherein R 3 and R4are each: 4? 9 0 4* 04 4 9. 4 V V it I It V I, I V Ii 4. 4 0 4~e* H wherein R 5 is hydrogen, alkyl having between about 1 20 carbon atoms, or cycloalkyl having between about 3 12 carbon atoms; or and and U 4 J wherein R3and R 4 when taken together are Cyoloalkyl-lf 2-diamino having between about 3 and 7 carbon dtoms, or alkenyl-1, 2-diamino having between about 2 arid 12 carbon atoms; and said complex is defined further as being substan- tially soluble in methanol or chloroform and substantially insoluble in water. I. 4" r' r IILI-- i mr~-- FRIDAY, FEB 198? -64-

73. The method of claim 72 wherein the carboxylato is an alkylcarboxylato having between about 6 and 12 carbon atoms. 4, t I it

74. The method of claim 72 wherein the carboxylato is an alkylcarboxylato having between about 5 and 20 carbon atoms, or an arylcarboxylato wherein aryl is naphthyl, phenyl, or alkylphenyl and the alkylphenyl has between about 7 and 16 carbon atoms, The method of claim 72 wherein the dicarboxylato is an alkylcarboxylato having between about 5 and 20 carbon 15 atoms, or an arylcarboxylato wherein aryl is naphthyl, phenyl, or alkylphenyl and the alkylphenyl has between about 12 and 18 carbon atoms.

76. The method of claim 72 wherein each hydrophobic radical function is defined further as being alkyl, aryl, aralkyl, alkenyl, cycloalkyl or cycloalkenyl or a combination thereof having between about 5 and about carbon atoms.

77. The method of claim 72 wherein the phospholipid is defined further as consisting essentially of phosphatidyl glycerol, phosphatidylcholine or a combination thereof. n i i ij

78. The method of claim 72 wherein the liposome is defined further as comprising cholesterol. Ics 1i p, i pr- ,FRIDAy IE 7

79. The method of claim 77 wherein the phosphatidyl glycerol is defined further as consisting essentially of dimyristoylphosphatidylglycerol and the phosphatidyl choline is defined further as consisting essentially of dimyristoylphosphatidylcholine. The method of claim 79 wherein the dimyristoylphos- phatidylglycerol and the dimyristoylphosphatidylcholine are defined further as being in a ratio between about 1 to and 10 to 1.

81. The method of claim 79 wherein the dimyristoylphos- It, 15 phatidylglycerol and the dimyristoylophosphatidylcholine are defined further as being in a ratio of about 3 to 7.

82. The method of claim 72 wherein the liposomes are defined further as having the complex and the phospholipid in a ratio between about 1 to 10 and about 1 to

83. The method of claim 78 wherein the liposomes are defined further as having the complex and the phospholipid 44 4 in a ratio of about 1 to

84. The method of claim 72 wherein the liposomes are defined further as being multilamellar. The method of claim 72 wherein the liposomes are defined further as being unilamellar. r; !U -t ro Z^ -66-

86. The method of claim 72 wherein the administering step is defined further as being intravenous, intraarterial, intramuscular, intralymphatic, intraperitoneal, subcu- taneous, intrapleural or intrathecal injection or by topical application or oral dosage.

87. The method of claim 72 wherein the administration is defined further as being repeated on a timed schedule. *9 9 *9 9 99 9 9 .99 9 *i .9 II *c 9 .4 9 It 9 9. c 9 59491

88. A method for preparing a platinum (II) four- coordinate complex having the formula: R3 R 1 Pt (II) R 4 R 2 wherein R 1 and R 2 are each carboxylato bearing a hydrophobic radical function or, when linked together, are a dicarboxylato bearing a hydrophobic radical function, and wherein R 3 and R 4 are each: Ni R Ir' FRDA Y, -6 FEB 1987 -67- wherein R 5 is hydrogen, alkyl having between about 1 and 20 carbon atoms, or cycloalkyl having between about 3 and 12 carbon atoms; or wherein R 3 and R 4 when linked together, are cycloalkyl-l,2-diamino having between about 3 and 7 carbon atoms, or alkenyl-l,2-diamino having between about 2 and 12 carbon atoms; and said complex is defined further as being substan- tially soluble in methanol or chloroform and substantially insolube in water; the method comprising: reacting a sulfato-trans- 15 R,R-l,2-diaminoalkane-platinum (II) complex with an alkali earth metal salt of a carboxylato monoanion bearing a hydrophobic radical function to produce said platinum (II) four-coordinate complex.

89. The method of claim 88 wherein R 5 is alkyl having between about 1 and 20 carbon atoms. 44 4 o o~ 4.4 4 4 4 4. 4 9 4.99 4 4. .4 1 9 *5 I .4 1 S C II S I I tI 45 44 4

90. The method of claim 88 wherein the reaction occurs in an aqueous environment.

91. The method of claim 88 wherein the sulfate salt of the alkali earth metal is removed by filtration, and the platinum complex is obtained by crystallization or by removal of the solvent by evaporation.

92. The method of claim 88 wherein the evaporation proceeds under reduced pressure at 45-500C. r i- I i I, S 9 4 I .r SFRIDAY, -6 FEB 1987 -68-

93. The method of claim 88 wherein the platinum compl*'a is further dried over a drying agent.

94. The method of claim 93 wherein the drying agent is phosphorus pentoxide. A sulfato-trans-R,R-l,2-diaminoalkane-platinum (II) complex produced by the method of claim 88.

96. A method of producing a liposome comprising: 15 providing platinum (II) four-coordinate complex having the formula: Pt (II) R 4 R 2 wherein R 1 and R 2 are each carboxylato bearing a hydrophobic radical function or, when linked together, are a dicarboxylato bearing a hydrophobic radical function, and wherein R 3 and R 4 are each: N R 5 s, 2 I -69- wherein R 5 is hydrogen, alkyl having between about 1 and 20 carbon atoms, or cycloalkyl having between about 3 and 12 carbon atoms; or wherein R 3 and R 4 when linked together are cycloalkyl-l,2-diamino having between about 3 and 7 carbon atoms, or alkenyl-1,2-diamino having between about 2 and 12 carbon atoms; said complex is defined further as being substan- tially soluble in methanol or chloroform and substantially insoluble in water; mixing said complex with phospholipid at a ratio of about 1:15 in a hydrophobic solvent; evaporating the hydrophobic solvent to produce a film of phospholipid and complex or lyophilizing the mixture to form a powder; dispersing the film or powder in an aqueous solution to produce liposomes. tz *c 0 eI t I ot a .;t t t ,3. C C t

97. The method of claim 96 wherein R 5 is alkyl having between about 6 and 12 carbon atoms. ~II

98. The method of claim 96 wherein the phospholipid is defined further as consisting essentially of phosphati- dylglycerol, phosphatidylcholine or a combination thereof.

99. The method of claim 96 wherein step is defined further as mixing said complex with phospholipid and cholesterol. i .4.i 1i 1 1 ril; ,FRIDAY, 6 FEB 1987

100. The method of claim 98 wherein the phosphatidyl- glycerol is defined further as consisting essentially of dimyristoylphosphatidyllycerol and the phosphatidylcholine is defined further as consisting essentially of dimyristoylphosphatidylcholine.

101. The method of claim 100 wherein the dimyristoylphos- phatidylglycerol and the dimyristoylphosphatidylcholine are defined further as being in a ratio between about 1-10 and 10-1. S*

102. The method of claim 100 wherein the dimyristoylphos- 15 phatidylglycerol and the dimyristoylphosphatidylcholine are defined further as being in a ratio of about 3 to 7. c

103. The method of claim 91 wherein the liposomes are CC defined further as comprising the complex and the phospholipid in a ratio between about 1 to 10 and about 1 to C CC C C C 25 104. The method of claim 96 wherein the liposomes are defined further as having the complex and the phospholipid in a ratio between about 1 to

105. The method of claim 96 wherein the liposomes are defined further as being multilamellar.

106. The method of claim 96 wherein an additional step is added of subjecting the liposomes to sonic oscillation to produce unilamellar liposomes. A rp"; i~ci I' FRIDAY, -6 FEB1987 -71-

107. The method of claim 96 wherein the step is defined further as comprising rotary evaporation. *0 Cr C C r ec C C 4 4461

108. A method for inhibiting the growth of tumors in a host comprising identifying a host bearing a tumor type known to generally contain cells whose growth is inhibited by platinum (II) complexes; and administering the liposomes of claim 44 to the host.

109. The method of claim 108 wherein the liposomes are further defined as being multilamellar.

110. The method of claim 108 wherein the liposomes are further defined as being unilamellar.

111. The method of claim 102 wherein the liposomes are administered parenterally. i '1

112. A method for inhibiting the growth of tumors in a 25 host comprising identifying a host bearing a tumor type known to generally contain cells whose growth is inhibited by platinum (II) complexes; and administering the complex of claim 1 to the host.

113. A method of inhibiting the metastatic spread of tumors in a host comprising identifying a host bearing a potentially metastatic or metastatic tumor of a type known generally to be inhibited by platinum (II) complexes; and administering the liposomes of claim 44 to the host. i I l;i 1 JI-..-i j .:II 1 1 SFRDAY -6 FEB 1987 -72-

114. The method of claim 113 wherein the liposomes are further deined as be 4 .ng multilamellar.

115. The method of claim 113 wherein the liposomes are further defined as being unilamellar.

116. The method of claim 113 wherein the liposomes are administered parenterally. I. b t 4 0 S u, 117. A method for inhibiting the metastatic spread of I tumors in a host comprising: identifying a host bearing a S 15 potentially metastatic or metastatic tumor of a type known generally to be inhibited by platinum (II) complexes; and administering the complex of claim 1 to the host.

118. The method of claim 117 wherein the complex is administered parenterally.

119. A method of vaccinating a host against the metastic spread of tumors comprising administering the liposomes of claim 44 to the host.

120. The method of claim 119 wherein the liposomes are Ir unilamellar.

121. The method of claim 119 wherein the liposomes are multilamellar. -73-

122. The method of claim 119 wherein the liposomes are administered intravenously.

123. The method of claim 119 wherein the metastatic spread is due to reticulosarcoma.

124. The complex of claim 16 wherein the decanoato are branched chains.

125. The complex of claim 23 wherein the decyl is neodecyl of the formula R' -OOC R R" wherein R, R' and R' are methyl, ethyl, or propyl, and the sum of the carbon atoms of R, ahd is 8.

126. The complex of claim 24 wherein the dicarboxylate is a branched chain.

127. The complex of claim 30 wherein the alkylcarboxylato are branched chains. *r 0 It U *p 0 *0 0 *.4 *6 0 *04 0 0 0*55

128. The are each

129. The branched

130. The are each complex of claim 34 branched chains. complex of claim chains. complex of claim 42 branched chains. wherein the alkylcarboxylato 37 wherein R 1 and R 2 are wherein the alkylcarboxylato ii f I 1 r .*l--,-lsfl s~~ f 74

131. The complex of claim 1 substantially as hereinbefore described with reference to the examples.

132. The method for preparing a platinum (II) four-coordinate complex according to claim 88 substantially as hereinbefore described with reference to the examples. DATED this 28th day of June, 1989. BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, By its Patent Arrorneys, DAVIES COLLISON. t I. I It ft t I ft II I I: I fit C I li i (4 r ,I ;c r I j